Lineage Cell Therapeutics Total Liabilities

Lineage Cell Therapeutics (LCTX) currently reports a total liabilities of $57M as of March 2026. That compares with $34M in the prior-year period — up 66.7% year over year. Use the charts on this page to explore Lineage Cell Therapeutics's total liabilities history and peer comparisons.

Lineage Cell Therapeutics's total liabilities increased from $34M to $57M — a 66.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lineage Cell Therapeutics reported $57M in total liabilities as of March 2026. That compares with $34M in the prior-year period — up 66.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $57M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lineage Cell Therapeutics, and consider following LCTX for alerts when major investors trade the stock.

Lineage Cell Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $57M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LCTX with unrelated industries.